Prices

Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act

Wednesday, December 8, 2021 at 9:00 a.m. PT/12:00 p.m. ET As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set…More

Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act

Wednesday, December 8, 2021 at 9:00 a.m. PT/12:00 p.m. ET As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set…More

Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act

As the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers. The…More

Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It

Most of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill –…More

AMA report: U.S. has “highly concentrated” payer markets that stifle competition  

About 73% of health insurance markets are highly concentrated, and in 46% of markets, one insurer had a share of 50% or more, a new report from the American Medical Association shows. The report comes a few months after President Joe Biden directed federal agencies to ramp up oversight of healthcare consolidation.

The Sleeper Health Cost Policy

In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.

Study: PE firms acquire hospitals with high operating margins, boosting them further

Hospitals acquired by PE firms tend to have higher operating margins than those that are not acquired — and that gap widens over time, a new study shows. But it is too early to say whether these glowing financial figures equate to better support for clinical care.

Are prices for diabetes drugs rising or falling?

Conventional wisdom would hold that the prices are rising…aren’t they? To correctly answer this question, one must define which prices you are talking about. Are we looking at the list price that is widely available or the net price after we take into account discounts are rebates life sciences firms pay? A paper by Sarpatwari …

Are prices for diabetes drugs rising or falling? Read More »

Analysis Examines the Implications of Price Transparency for Providers and Patients as New Rules Go into Effect

A new KFF analysis examines how new federal rules on price transparency for health services may affect patient decision-making and market pricing. As of January 1, 2021, the United States Department of Health and Human Services requires that hospitals publish payer-negotiated rates for common services on their websites. A second set of rules, which requires…More

Health Policy Resources for Covering the 2020 Elections

As the 2020 Election Day approaches, many candidates continue to focus on health care issues, including on the public health and economic response to COVID-19, the future of the Affordable Care Act, health care costs and abortion. To help reporters understand and cover these issues, KFF offers independent, non-partisan policy analysis, polling and other research and…More

Moderna Prices its COVID-19 Vaccine at $32-$37 per Dose for Smaller Volume Agreements

Shots: For smaller volume agreements, the company has priced its COVID-19 vaccine ranging from $32-$37/ dose, higher than the price of Pfizer’s vaccine candidate The company is in talks with several countries for supply agreements of its vaccine, adding that it had already received about $400M for supply. The P-III study of mRNA-1273 is being …

Moderna Prices its COVID-19 Vaccine at $32-$37 per Dose for Smaller Volume Agreements Read More »